RESULTS
The amount of lactic acid produced during the incubation was significantly lower in No. 1 than in No. 4, but it showed a significant increase in Nos. 2 and 3. The mixture of 95% N2 and 5% CO2 was employed as atmosphere. An increase in lactic acid production by addition of orotic acid or uridine was also observed in case of the control, but less significantly in degree (cf. Table II and Fig. 1 ). At present it is not fully understandable how Gal-1-P should affect cellular metabolism. A probable postulation is drawn from Najjar and Gisburg's observations) that Gal-1-P has in vitro an inhibitory effect on phosphoglucomutase which catalyzes the conversion of glucose-l-phosphate?tglucose-6-phosphate. This kind of inhibition could be reasonably expected as an instance of competitive inhibition arising from a very slight structural difference between glucose-1 phosphate and galactose-l-phosphate, this difference being only in the configura tion of the OH and H radicals on the fourth carbon atom. Such an inhibition of phosphoglucomutase by Gal-1-P accumulated in the tissues would in vivo result in an depressed glycogenolysis which would thus be responsible for cellular injury.
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As the results given in this paper revealed, the erythrocytes of a galactosemic child one of our own patients showed a remarkable accumulation of hexose-phosphate when incubated with galactose (cf . Fig. 2 ). This may be explained by a possible accumulation of Gal-1-P in erythrocytes due to a defect of Gal-1-P uridyl transferase. This finding suggesting a block on way of galactose utilization, was also confirmed by our own results that the radioactivity of P32 added to the incubation mixture was found to be much higher in hexose phosphate fraction of galactosemic erythrocytes than in that of the normal erythrocytes (cf. Fig. 3) .
Furthermore, the lactic acid produced during the incubation of erythrocytes with galactose was lower in galactosemic erythrocytes as compared with that in the normal erythrocytes (cf. Fig. 1 ). This result also indicates an existence of a block on way of galactose utilization, since galactose is, in normal erythrocyte, converted to glucose-1-phosphate and led to lactic acid via the Embden Meyerhof pathway. Although a considerable amount of lactic acid was produced even in galactosemic erythrocytes in this experiment, this may be due mainly to the utilization of glucose contained in blood itself.
Our own experiment clearly showed that the above-mentioned disturbance in galactosemic erythrocytes an accumulation of hexose-phosphate and a lower production of lactic acid during the incubation with galactose was mitigated obviously by an addition of orotic acid or uridine to the incubation mixture (cf. Figs. 1, 2 and 3 ). This evidence, combined with our clinical observa tion reported previously1) that the orotic acid therapy brought about an improvement of galactosuria and galactose tolerance as well as of clinical symptoms, indicates that orotic acid has a beneficial effect on the galactose metabolism of congenital galactosemia.
It is well known that orotic acid is a precursor of uridine nucleotide,1°) and UDPG, one of uridine nucleotides, is known to be an essential factor for galactose metabolism11-13) (cf. Table IV) .
Our own results that uridine as well as orotic acid had a similar effect on improving the galactose utilization in galactosemic erythrocytes may strongly support that the beneficial effect of orotic acid is based on an action of uridine nucleotide derived from orotic acid (cf. Fig. 4) .
In the normal erythrocytes (or liver) the surplus of orotic acid may increase the production of UDPG, thus resulting in acceleration of Reaction 2 in galactose metabolism (cf. Table IV) . On the other hand, in the case of galactosemia, galactose metabolism should not be accelerated even if UDPG production is enhanced by an addition of orotic acid, because there is a defect of Gal-1-P uridyl transferase. How will then be explained the beneficial effect of orotic acid upon galactose metabolism in congenital galactosemia? In this respect, it is worthy to notice an existence of accessory pathway by UDPGa1 pyrophosphorylase which It has so far been the only therapy for galactosemia to eliminate galactose from the diet. It is, however, difficult in practice to give a galactose-free diet to infants because milk or milk products are the major source of galactose .
The present results showed, as we believe, biochemical evidences for a promising orotic acid treatment1) of congenital galactosemia without eliminating milk or milk products from the diet. Furthermore there is a possibility that galactose-l-phosphate, which is accumulated in the tissues of the galactosemic patient and which is supposed to be responsible for cellular injury, might be diminished via the accessory pathway by orotic acid therapy.
CONCLUSIONS
The effect of orotic acid on galactose metabolism of congenital galactosemia was in vitro investigated using blood samples from the patients. 
